efficacy

September 12, 2018

Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial

News

Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory multiple myeloma, according to early results of ... Read more

January 15, 2018

Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report

News

Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical company. The first dose (8 mg ... Read more

November 8, 2017

CLR 131 Continues to Show Survival Benefit in Heavily Treated Multiple Myeloma Patients

News

A recent update on Cellectar Biosciences’ Phase 1 trial revealed that heavily treated myeloma patients who received the lowest dose of CLR 131 survived for a median of 26.2 months. While the ... Read more

October 6, 2017October 6, 2017

Cellectar’s CLR 131 Shows Positive Phase 1 Trial Results for Heavily Treated Myeloma Patients

News

All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said. Participants had received more than five ... Read more

June 30, 2017

Bristol-Myers Squibb Issues Four-year Follow-up Findings for Empliciti Triple Combo Therapy

News

Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3 ELOQUENT-2 trial (NCT01239797) after ... Read more